Community-acquired pneumonia (CAP) remains a significant global health burden, affecting 3.3 million adults in Europe each year and leading to approximately 1.5 million adult hospitalizations annually in the United States. Rapid and accurate identification of the causative pathogen remains a major challenge in pneumonia diagnosis, despite significant advances in clinical management.
This is particularly relevant for Streptococcus pneumoniae, the most common bacterial cause of CAP, and Legionella species, including Legionella pneumophila, which, although less frequent, are associated with more severe disease and higher mortality.
Timely pathogen identification is critical for guiding appropriate antimicrobial stewardship (AMS) and improving patient outcomes, however, the diagnostic pathway for pneumonia is often constrained by trade-offs between speed, accuracy, and practicality.
Diagnostic complexity in pneumonia care
One of the primary difficulties in managing CAP is that infections caused by different pathogens often present with indistinguishable clinical features, including symptoms such as cough, fever, and breathlessness, alongside nonspecific radiological findings. This makes it difficult to differentiate between “typical” and “atypical” pneumonia based on clinical assessment alone, making laboratory testing essential to confirm etiology.
Traditional diagnostic approaches using culture-based methods remain a reference standard but are limited by their speed, requiring several days to confirm S. pneumoniae—and sometimes weeks for Legionella species.
Molecular techniques, including PCR, offer better sensitivity and faster turnaround times but depend on high-quality respiratory samples and can be costly or difficult to interpret in routine settings.
Sampling can also be problematic; bronchoalveolar lavage (BAL) is considered optimal for many molecular and culture-based methods, but collection is invasive and often impractical outside intensive care. Sputum samples are easier to obtain but are frequently of poor quality, limiting their diagnostic reliability and often leaving clinicians without definitive results during the critical early phase of treatment.
Consequences of diagnostic uncertainty
Without that crucial early diagnosis, clinicians frequently start treating with a broad-spectrum antibiotic therapy that potentially covers a wide range of potential pathogens. However, while this approach is sometimes necessary in acute care, it does contribute to the growing problem of antimicrobial resistance, or AMR.
Recent estimates suggest that AMR was associated with approximately 1.14 million deaths globally in 2021, with projections indicating a substantial increase in the coming decades.
Pneumonia is one of the most common conditions to rely on early empirical antibiotic use, but prolonged or inappropriate therapy ultimately leads to increased healthcare costs, extended hospital stays, and less effectiveness of frontline treatments.
These challenges reinforce the importance of diagnostic stewardship and reliable diagnostic tools in targeted therapy, with the aim of reducing unnecessary antibiotic exposure, and adhering to AMS programs.
The role of urinary antigen testing
Urinary antigen tests (UATs) have emerged as valuable tools for rapid diagnosis of pneumonia and are recommended in European and international CAP guidelines for hospitalized patients.
UATs provide a fast, noninvasive method for detecting specific bacterial antigens excreted in urine, and they offer several practical advantages. Urine samples are easy to collect, pose minimal infection risk, and remain valid even after antibiotic therapy has begun because antigen excretion persists for several days. UATs are also preferable for patients who are unable to produce high-quality respiratory samples, such as the elderly or critically ill.
Conventional UATs, typically based on lateral flow immunochromatographic formats, can deliver results within minutes and are widely used in hospital settings.
However, these assays are not without limitations. Many detect only a restricted range of L. pneumophila serogroups—often limited to serogroup 1—and a subset of pneumococcal serotypes.
Visual interpretation of results can also introduce subjectivity and potential variability between operators, and the lack of standardization and limited traceability associated with manual testing can pose issues for quality control in laboratories.
Automating diagnostic solutions
There is increasing interest in automated, laboratory-based immunoassay platforms that extend the capabilities of traditional UATs and address these drawbacks, combining the simplicity of urine-based testing with an integrated workflow.
Automated lab systems can perform sample processing, detection, and interpretation of data all within a single platform, reducing hands-on time and minimizing the risk of human error.
Results are objective, instrument-based measurements rather than visual interpretation, and they can easily be integrated into laboratory information systems, or LIS, for full traceability, and audit and accreditation compliance.
The throughput capabilities of automation also make these systems well suited to busy clinical laboratories handling large sample volumes.
Expanding detection coverage
Another important advantage of newer immunoassay approaches is that they broaden diagnostic coverage of potential causative organisms, including some that are frequently missed by some technologies.
For example, traditional tests that focus on L. pneumophila serogroup 1 may miss infections caused by other serogroups or by species such as L. longbeachae, which has been increasingly reported in certain regions.
Similarly, S. pneumoniae encompasses a wide range of serotypes, and assays with broader inclusivity can improve detection across diverse epidemiological settings.
Expanding antigen targets in this way also gives local and global health bodies far better surveillance data about infectious disease rates and emerging pathogens.
Impact on workflows and decision making
From a laboratory perspective, automating UATs reduces manual workload and streamlines workflows, decreasing technician hands-on time and minimizing transcription errors.
Standardized processes and digital reporting of results also improve efficiency which, from a clinical perspective, feeds into earlier pathogen-specific diagnosis and targeted antibiotic treatments, as well as public health reports for notifiable pathogens such as Legionella.
Bridging the gap between speed and accuracy
The evolving landscape of pneumonia diagnostics reflects a broader need to reconcile rapid testing with analytical reliability and operational efficiency. While traditional methods remain valuable, their limitations highlight the potential of complementary approaches that can rapidly deliver accurate and actionable results.
Automated urine antigen tests, for example, combine noninvasive sample collection with faster detection capabilities and better laboratory integration.
By addressing many of the shortcomings of conventional rapid tests, these technologies have the potential to improve diagnostic precision, optimize antibiotic use, and improve overall patient care.
The role of diagnostics will remain central as the burden of pneumonia persists and antimicrobial resistance continues to rise, with advances in testing technology likely to shape the future of infectious disease management.
